Skip to main
NTRA

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 33%
Buy 60%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Natera Inc. is projected to experience significant revenue growth driven by its Signatera test, with a notable increase in clinical and biopharmaceutical use anticipated this year. The company is also pursuing expanded reimbursement coverage for Signatera across additional cancer types, which is expected to enhance average selling prices, gross margins, and operating cash flow. In the most recent quarter, Natera reported a remarkable revenue beat of approximately $80 million and raised its 2025 revenue guidance by $160 million, highlighting strong market demand and operational performance.

Bears say

Natera Inc faces pressure on its profit margins due to anticipated reductions in in-network pricing as it expands its target market, which may include more average-risk patients. The company is also at risk of significant declines in stock value should it encounter negative developments related to regulatory issues, reimbursement challenges, or delays in product launches, all of which could impact its financial performance. Furthermore, competitive pressures from other diagnostic companies, like Guardant Health, highlight the importance of reimbursement coverage and compelling clinical data, which are crucial for Natera's growth and market expansion.

Natera (NTRA) has been analyzed by 15 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 60% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 15 analysts, Natera (NTRA) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $238.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $238.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.